Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine with anticonvulsant properties. It is primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure disorders.
### Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
* May be used for other seizure types as per local protocol and guidelines.
### Adult Dosing
* **LGS:** Initial dose is typically 5 mg twice daily. Titrate slowly as needed.
* **Maximum Dose:** Generally 20 mg twice daily (40 mg/day) for LGS. Higher doses may be used in specific cases under close medical supervision.
### Pediatric Dosing
* **LGS (2 to less than 10 years of age):** Initial dose is typically 2.5 mg twice daily. Titrate slowly as needed.
* **Pediatric Maximum Dose:** Generally 10 mg twice daily (20 mg/day) for LGS.
* **LGS (10 years of age and older, or weighing 30 kg or more):** Initial dose is typically 5 mg twice daily. Titrate slowly as needed.
* **Pediatric Maximum Dose:** Generally 20 mg twice daily (40 mg/day) for LGS.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Lower doses may be indicated.
* **Renal Impairment:** Use with caution. No specific dose adjustment is routinely recommended, but careful monitoring is advised.
* **Concomitant Medications:** Consider potential interactions (see below).
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
### Adverse Effects
* **Common:** Somnolence, increased appetite, weight gain, constipation, drooling, fatigue, aggression, irritability, difficulty with coordination.
* **Serious:** Suicidal ideation/behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase clobazam levels.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam levels.
* **Other Anticonvulsants:** Monitor for altered efficacy or increased CNS side effects.
### Monitoring
* **Efficacy:** Monitor for reduction in seizure frequency.
* **Safety:** Monitor for somnolence, dizziness, coordination problems, and any signs of respiratory depression.
* **Suicidality:** Monitor for emergent suicidal thoughts and behaviors.
* **Withdrawal Symptoms:** Monitor for symptoms upon discontinuation (anxiety, insomnia, tremors, nausea, seizures).
### Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Treatment should be initiated by a physician experienced in the treatment of epilepsy.
* Withdrawal of clobazam should be gradual to minimize the risk of increased seizure frequency and withdrawal symptoms.
* Patients and caregivers should be informed about the risk of suicidal ideation and behavior and advised to report any new or worsening symptoms immediately.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making clinical decisions.
